Status:
UNKNOWN
Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients
Lead Sponsor:
Beni-Suef University
Conditions:
Polycystic Ovary Syndrome
Eligibility:
FEMALE
20-40 years
Phase:
PHASE2
PHASE3
Brief Summary
The Study aims to determine the proposed positive influence of Sitagliptin in manipulating hormonal , metabolic and inflammatory parameters in the treatment of Polycystic ovary syndrome and subsequent...
Detailed Description
Study Design : a Prospective Randomized Controlled Trial. A Total of 80 infertile Adult Females aged between 18 and 45 years currently diagnosed with Polycystic ovary syndrome , Meeting the Diagnosis...
Eligibility Criteria
Inclusion
- polycystic ovary syndrome usually diagnosed based on the Rotterdam criteria if 2 of 3 criteria are present:
- oligo- and/or anovulation
- hyperandrogenism (HA) (clinical and/or biochemical)
- polycystic ovary morphology (PCOM) on ultrasonography (either 12 or more follicles measuring 2-9 mm in diameter and/or an increased ovarian volume \>10 cm3).
Exclusion
- congenital adrenal hyperplasia
- Brittle control of a thyroid disorder
- Diabetic on Metformin or any another antidiabetic drugs affecting insulin resistance
- chronic kidney disease
- liver dysfunction
- documented use of oral hormonal contraceptives and hormone-releasing implants in the past 6 months prior to study entry 7.Lipid lowering Consumption
Key Trial Info
Start Date :
July 30 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05972928
Start Date
July 30 2023
End Date
October 30 2023
Last Update
August 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beni-suef university Hospital
Banī Suwayf, Beni Suweif Governorate, Egypt, 62521